DBV Technologies S.A. (DBVT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7900 |
| Open | 0.8100 |
| Bid | 0.7803 x 900 |
| Ask | 0.8500 x 1000 |
| Day's Range | 0.7910 - 0.8199 |
| 52 Week Range | 0.6500 - 2.3700 |
| Volume | |
| Avg. Volume | 344,193 |
| Market Cap | 159.25M |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.01 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DBVT
Related Research
- DBV Technologies S.A.Daily – Vickers Top Buyers & Sellers for 11/24/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat15 days agoArgus Research
GlobeNewswireInformation regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without v
- GlobeNewswire
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.55.9% of subjects completed the oral food challenge at a cumulative dose of 3,444
- GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 10/31/2023 96,288,553 Total gross of voting rights: 96,288,553 Total net* of voting rights: 96,084,083 * Net total = total number of voting rights attached to shares – shares w
